EITVent — EIT-Guided PEEP and Mortality in ARDS

1. Publication

• Title: Electrical impedance tomography-guided positive end-expiratory pressure and mortality of patients with the acute respiratory distress syndrome
• Acronym: EITVent
• Year & Journal: American Journal of Respiratory and Critical Care Medicine, 2026;212(3):440-451
• Citation: Yuan X, Zhong M, Li Z, et al; Chi-ARDS Net (Chinese ARDS Research Network). Electrical impedance tomography-guided positive end-expiratory pressure and mortality of patients with the acute respiratory distress syndrome: the EITVent randomized clinical trial. Am J Respir Crit Care Med. 2026;212(3):440-451. doi:10.1093/ajrccm/aamaf125

2. Context & Rationale

Background: Physiological studies suggested bedside EIT-guided personalized PEEP titration — balancing lung overdistension against collapse — improves ventilation-perfusion matching without harming pulmonary circulation, compared with standard lower PEEP/FiO2 table strategies. However, the interaction between lung recruitability and ARDS etiology on treatment effect remained unclear.

Research Question/Hypothesis: In patients with moderate-to-severe ARDS, does EIT-guided PEEP titration reduce 28-day mortality compared with the standard lower PEEP/FiO2 table?

Why This Matters: PEEP titration remains one of the most consequential, unresolved bedside decisions in ARDS ventilator management; EIT offers a theoretically personalized, physiology-driven alternative to table-based approaches.

3. Design & Methods

• Study Type: Randomized clinical trial (multicenter, Chinese ARDS Research Network)
• Setting & Centers: Chi-ARDS Net centers, China
• Population:
• Inclusion: Moderate-to-severe ARDS
• Exclusions: Not detailed in available trial text
• Intervention: EIT-guided PEEP titration, including a recruitment maneuver (RM) performed before and after a decremental PEEP trial to identify personalized PEEP balancing overdistension/collapse
• Comparator: Lower PEEP/FiO2 table strategy (standard ARDSNet-style approach)
• Blinding: Not detailed in available trial text (device-based intervention typically open-label)
• Statistical Power & Follow-Up: Trial was terminated early; primary outcome 28-day mortality. A prespecified subgroup analysis used the recruitment-inflation ratio method to classify lung recruitability (90/190 patients [47.4%] classified as higher recruitability).

4. Key Results

Trial stopped early — authors note this may have left the study underpowered to detect a clinically important difference.

Notable finding: Overall mortality in this trial was higher than reported in other ARDS PEEP RCTs; authors attribute this partly to the combination of repeated recruitment maneuvers and protocol-induced derecruitment during the decremental PEEP trial, which may have offset benefits in the EIT-guided group despite lower... (mechanism not fully specified in available trial text).

5. Internal Validity Assessment

• Randomization & Allocation: Not detailed in available trial text.
• Protocol Adherence & Separation: EIT-guided group received recruitment maneuvers and decremental PEEP trials not performed in the control (standard table) group — the intervention itself involved additional procedural steps beyond PEEP level alone.
• Blinding & Detection Bias: Not detailed in available trial text; mortality is an objective endpoint less susceptible to detection bias regardless.
• Missing Data & Sensitivity Analyses: Not reported in available trial text.
• Overall Internal Validity Conclusion: Low-Moderate — early termination is the dominant limitation; the trial explicitly states it "may have been underpowered to detect a clinically important difference," and the higher-than-expected overall mortality raises questions about whether repeated recruitment maneuvers introduced procedural harm that could have masked a true EIT benefit.

6. External Validity Assessment

• Population Representativeness: Chinese multicenter ARDS population with moderate-to-severe disease; recruitability assessed via a specific method (recruitment-inflation ratio) not universally used at the bedside.
• Practice Context: EIT equipment and expertise for both titration and recruitability phenotyping are not widely available outside specialized/research ICUs.
• Overall External Validity Conclusion: Limited — requires specialized equipment and recruitability-phenotyping methodology not in routine global practice; the recruitability subgroup finding, if real, would only apply to the ~47% of ARDS patients with higher recruitability by this specific method.

7. Strengths & Limitations

Strengths:

• Directly tests a physiologically grounded, individualized PEEP-titration strategy against standard practice
• Prespecified recruitability subgroup analysis using an explicit, reproducible method (recruitment-inflation ratio)
• Clinically important, hypothesis-generating subgroup signal (HR 0.49 in higher-recruitability patients)

Limitations:

• Early termination, explicitly acknowledged by authors as likely underpowering the primary analysis
• Overall mortality higher than comparable trials, raising concern about procedural harm from repeated recruitment maneuvers
• Overall (non-subgroup) result is a clear null, and subgroup findings require independent confirmation before practice change
• Details of randomization, blinding, and missing-data handling not available in accessible trial text

8. Interpretation & Practice Impact

• Clinical Implications: Does not support routine EIT-guided PEEP titration as a global ARDS strategy; the recruitability-based subgroup signal suggests a possible role for EIT specifically in phenotyping which patients might benefit from higher, individualized PEEP — but this requires prospective confirmation.
• Mechanistic Coherence: The dissociation between the neutral overall result and the strong recruitability-subgroup signal is consistent with ARDS heterogeneity — not all ARDS patients respond the same way to higher PEEP, and EIT may have value as a selection tool rather than a universal titration tool.
• Systems-Level Takeaway: Raises the discussion (per accompanying commentary) of whether EIT should be used selectively for precision-medicine-style patient selection rather than as routine daily exhaustive PEEP titration.

9. Controversies & Subsequent Evidence

• Editorial Commentary: An accompanying editorial explicitly frames the central question as "how much titration is too much?" — questioning whether the repeated recruitment maneuvers required for EIT-guided titration may have introduced net harm that obscured a real physiological benefit.
• Guideline Integration: Not yet incorporated into major ARDS ventilation guidelines; remains an active research question given the early termination and the tension between the neutral overall result and the recruitability subgroup signal.

10. Summary & Executive Takeaway

Summary: EITVent, an early-terminated Chinese multicenter RCT, randomized moderate-to-severe ARDS patients to EIT-guided personalized PEEP or standard lower PEEP/FiO2 table. Overall 28-day mortality was not significantly different (55.9% vs 52.6%; HR 0.96, 95% CI 0.65–1.41, P=0.821), but a prespecified subgroup with higher lung recruitability showed a large mortality reduction with EIT-guided (higher) PEEP (35.6% vs 60.0%; HR 0.49, 95% CI 0.26–0.91, P=0.024).

Overall Takeaway: EITVent's neutral overall result, combined with early termination and higher-than-expected mortality, argues against routine EIT-guided PEEP titration for all ARDS patients — but its recruitability-subgroup signal is a genuinely promising, hypothesis-generating finding suggesting EIT may have more value as a patient-selection tool for individualized PEEP strategy than as a universal titration protocol.

11. Bibliography

• Yuan X, Zhao Z, Chao Y, et al. Effects of early versus delayed application of prone position on ventilation... [related Chi-ARDS Net work].
• Accompanying editorial: Rethinking electrical impedance tomography–guided PEEP in ARDS: how much titration is too much? AJRCCM. 2026.